Publication|Articles|December 18, 2024
Supplements and Featured Publications
- Year in Review: Multiple Myeloma
Year in Review: Multiple Myeloma
Listen
0:00 / 0:00
Advertisement
This 2024 multiple myeloma year in review recaps clinical trial data presented at major conferences and important FDA updates, including the April 2024 vote by the Oncologic Drug Advisory Committee that measures of minimal residual disease (MRD) negativity could be part of a surrogate end point in trials.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Communication of Launch Prices by Drug Companies, 2022-2024
2
Top 5 Most-Read News Stories of 2025
3
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
4
Bispecifics in New Combos, New Uses, and Earlier Lines of Treatment in Myeloma
5





































